Immucell (ICCC) Total Current Liabilities (2010 - 2026)

Immucell (ICCC) has reported Total Current Liabilities for 17 consecutive years, with $4.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities changed 0.24% year-over-year to $4.4 million; the trailing twelve-month figure through Jun 2026 stood at $4.4 million (changed 0.24% YoY), and the FY2025 full-year result was $4.0 million, down 9.84% from the prior year.
• Total Current Liabilities advanced to $4.4 million in Q2 2026 per ICCC's latest filing, from $4.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $4.6 million in Q2 2024 and bottomed at $2.6 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $3.8 million across 5 years, with a median of $4.0 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 53.52% in 2023, then decreased 10.48% in 2025.
• Over 5 years, Total Current Liabilities stood at $3.1 million in 2022, then jumped by 36.63% to $4.2 million in 2023, then increased by 5.12% to $4.4 million in 2024, then declined by 9.84% to $4.0 million in 2025, then rose by 11.5% to $4.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $4.4 million, $4.0 million, and $4.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.